[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 21, 1999

Alendronate and Fracture Prevention

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(3):231. doi:10.1001/jama.282.3.231

To the Editor: We believe that due caution must be taken when interpreting the results of the Fracture Intervention Trial II (FIT-II),1 since the conclusion appears to be based on post hoc subgroup analysis. Instead, the efficacy based on the intent-to-treat analysis should be considered, ie, the effect of alendronate achieved according to analysis based on the study groups to which they were originally randomized, even though the classification of low bone mineral density (BMD) was changed during the study, resulting in one third of the study population actually having higher BMD than intended.

First Page Preview View Large
First page PDF preview
First page PDF preview
×